These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
117 related articles for article (PubMed ID: 37587797)
1. Absolute and Relative Bioavailability of Oral Solid Dosage Formulations of Deucravacitinib in Humans. Chimalakonda A; Li W; Marchisin D; He B; Singhal S; Deshpande P; Brown J; Aras U; Murthy B Clin Pharmacol Drug Dev; 2023 Oct; 12(10):956-965. PubMed ID: 37587797 [TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and Safety of the Tyrosine Kinase 2 Inhibitor Deucravacitinib in Healthy Chinese Subjects. Jing S; Lin Y; Dockens R; Marchisin D; He B; Girgis IG; Chimalakonda A; Murthy B; Aras U Dermatol Ther (Heidelb); 2023 Dec; 13(12):3153-3164. PubMed ID: 37981596 [TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and Safety of Posaconazole Administered by Intravenous Solution and Oral Tablet in Healthy Chinese Subjects and Effect of Food on Tablet Bioavailability. Li H; Wei Y; Zhang S; Xu L; Jiang J; Qiu Y; Mangin E; Zhao XM; Xie S Clin Drug Investig; 2019 Nov; 39(11):1109-1116. PubMed ID: 31432392 [TBL] [Abstract][Full Text] [Related]
4. Differential pharmacokinetics of diclofenac potassium for oral solution vs immediate-release tablets from a randomized trial: effect of fed and fasting conditions. Chen C; Bujanover S; Kareht S; Rapoport AM Headache; 2015 Feb; 55(2):265-75. PubMed ID: 25546369 [TBL] [Abstract][Full Text] [Related]
5. Bioavailability of two oral-tablet and two oral-suspension formulations of naproxen sodium/paracetamol (acetaminophen): single-dose, randomized, open-label, two-period crossover comparisons in healthy Mexican adult subjects. Palma-Aguirre JA; Villalpando-Hernández J; Novoa-Heckel G; Oliva I; Cariño L; López-Bojórquez E; Burke-Fraga V; Namur S; González-de la Parra M Clin Ther; 2009 Feb; 31(2):399-410. PubMed ID: 19302912 [TBL] [Abstract][Full Text] [Related]
6. Evaluation of Absolute Oral Bioavailability and Bioequivalence of Ribociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, in Healthy Subjects. Ji Y; Abdelhady AM; Samant TS; Yang S; Rodriguez Lorenc K Clin Pharmacol Drug Dev; 2020 Oct; 9(7):855-866. PubMed ID: 32706937 [TBL] [Abstract][Full Text] [Related]
7. Bioavailability of two oral suspension and two oral tablet formulations of acyclovir 400 mg: two single-dose, open-label, randomized, two-period crossover comparisons in healthy Mexican adult subjects. Palma-Aguirre JA; Absalón-Reyes JA; Novoa-Heckel G; de Lago A; Oliva I; Rodríguez Z; González-de la Parra M; Burke-Fraga V; Namur S Clin Ther; 2007 Jun; 29(6):1146-52. PubMed ID: 17692728 [TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and pharmacodynamics of single rising intravenous doses (0.5 mg-10 mg) and determination of absolute bioavailability of the dipeptidyl peptidase-4 inhibitor linagliptin (BI 1356) in healthy male subjects. Retlich S; Duval V; Ring A; Staab A; Hüttner S; Jungnik A; Jaehde U; Dugi KA; Graefe-Mody U Clin Pharmacokinet; 2010 Dec; 49(12):829-40. PubMed ID: 21053992 [TBL] [Abstract][Full Text] [Related]
9. Preclinical and Clinical Pharmacokinetics and Bioavailability in Healthy Volunteers of a Novel Formulation of the Selective P2X3 Receptor Antagonist Eliapixant. Francke K; Chattopadhyay N; Klein S; Rottmann A; Krickau D; van de Wetering J; Friedrich C Eur J Drug Metab Pharmacokinet; 2023 Jan; 48(1):75-87. PubMed ID: 36469250 [TBL] [Abstract][Full Text] [Related]
10. Comparative pharmacokinetics and bioavailability of gemifloxacin administered as an intravenous 200 mg formulation or an oral 320 mg tablet. Kim MJ; Lim HS; Cho SH; Bae KS Clin Drug Investig; 2014 Mar; 34(3):195-201. PubMed ID: 24385283 [TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of Morphine Sulfate Orodispersible Tablets and Bioequivalence with Immediate-Release Oral Morphine Sulfate Formulations in Healthy Adult Subjects Under Fasting Conditions: Single-Dose Comparative Bioavailability Studies. Atrux-Tallau N; Naimi Z; Jaudinot EO Clin Drug Investig; 2022 Dec; 42(12):1101-1112. PubMed ID: 36331670 [TBL] [Abstract][Full Text] [Related]
13. Single-dose bioavailability of levetiracetam intravenous infusion relative to oral tablets and multiple-dose pharmacokinetics and tolerability of levetiracetam intravenous infusion compared with placebo in healthy subjects. Ramael S; De Smedt F; Toublanc N; Otoul C; Boulanger P; Riethuisen JM; Stockis A Clin Ther; 2006 May; 28(5):734-44. PubMed ID: 16861095 [TBL] [Abstract][Full Text] [Related]
14. The effect of food on the absorption and pharmacokinetics of rivaroxaban. Stampfuss J; Kubitza D; Becka M; Mueck W Int J Clin Pharmacol Ther; 2013 Jul; 51(7):549-61. PubMed ID: 23458226 [TBL] [Abstract][Full Text] [Related]
15. Safety, Tolerability, and Pharmacokinetic Properties of Intravenous Delafloxacin After Single and Multiple Doses in Healthy Volunteers. Hoover R; Hunt T; Benedict M; Paulson SK; Lawrence L; Cammarata S; Sun E Clin Ther; 2016 Jan; 38(1):53-65. PubMed ID: 26718605 [TBL] [Abstract][Full Text] [Related]
16. Abacavir: absolute bioavailability, bioequivalence of three oral formulations, and effect of food. Chittick GE; Gillotin C; McDowell JA; Lou Y; Edwards KD; Prince WT; Stein DS Pharmacotherapy; 1999 Aug; 19(8):932-42. PubMed ID: 10453964 [TBL] [Abstract][Full Text] [Related]
17. Absolute oral bioavailability of traxoprodil in cytochrome P450 2D6 extensive and poor metabolisers. Taylor TJ; Diringer K; Russell T; Venkatakrishnan K; Wilner K; Crownover PH; Benincosa LJ; Gibbs MA Clin Pharmacokinet; 2006; 45(10):989-1001. PubMed ID: 16984212 [TBL] [Abstract][Full Text] [Related]
18. Relative bioavailability and effects of a high fat meal on single dose cilostazol pharmacokinetics. Bramer SL; Forbes WP Clin Pharmacokinet; 1999; 37 Suppl 2():13-23. PubMed ID: 10702883 [TBL] [Abstract][Full Text] [Related]
19. Clinical Bioavailability of the Novel BACE1 Inhibitor Lanabecestat (AZD3293): Assessment of Tablet Formulations Versus an Oral Solution and the Impact of Gastric pH on Pharmacokinetics. Ye N; Monk SA; Daga P; Bender DM; Rosen LB; Mullen J; Minkwitz MC; Kugler AR Clin Pharmacol Drug Dev; 2018 Mar; 7(3):233-243. PubMed ID: 29319935 [TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics, absolute bioavailability, and absorption characteristics of lamivudine. Yuen GJ; Morris DM; Mydlow PK; Haidar S; Hall ST; Hussey EK J Clin Pharmacol; 1995 Dec; 35(12):1174-80. PubMed ID: 8750368 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]